Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Nearing Application For Japanese Approval Of Razadyne

This article was originally published in PharmAsia News

Executive Summary

Janssen Pharmaceutical KK of Japan says its Phase III trial of an Alzheimer's disease drug has moved to the point it plans to apply for marketing approval in Japan next year. Razadyne (galantamine hydrobromide) by Janssen's parent, Johnson & Johnson, already is marketed in more than 50 countries for inhibiting cholinesterase and modulating nicotinic receptors in the brain to promote synthesis of acetylcholine. Razadyne would compete in the Japanese market against Eisai's Aricept (donepezil hydrochloride). (Click here for more - prescription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel